Evaluation of symmetric dimethylarginine in cats with acute kidney injury and chronic kidney disease

Efficacy of Urine Asymmetric Dimethylarginine Concentration to Predict Azotemia in Hyperthyroid Cats After Radio-Iodine Treatment

BACKGROUND

Hyperthyroidism can mask concurrent chronic kidney disease in cats, and no accurate biomarkers are available to predict which cats will develop renal azotemia after radioiodine (131I) treatment.

HYPOTHESIS/OBJECTIVES

To evaluate the potential of serum and urinary metabolites and metabolite ratios to predict post-131I renal azotemia in hyperthyroid cats.

ANIMALS

Hyperthyroid cats (n = 31), before and (3-12 months) after treatment with 131I at the Faculty of Veterinary Medicine (Ghent University, Belgium).

METHODS

Retrospective study. Optimized and validated feline extraction and analysis protocols were employed for metabolic profiling of urine and serum samples using ultra-high performance liquid chromatography-high-resolution mass spectrometry. A dual strategy of cross-validated univariate and penalized multivariate logistic regression was applied to determine predictivity (i.e., area under the curve [AUC], accuracy, sensitivity, and specificity) of individual biomarkers and panels.

RESULTS

All hyperthyroid cats were non-azotemic before 131I administration. After 131I treatment, 7 cats became persistently (≥ 2 timepoints) azotemic while 24 remained non-azotemic. Urinary asymmetric dimethylarginine (ADMA) was identified as a pivotal predictor of post-131I azotemia in both univariate and multivariate modeling. When employed as a standalone biomarker, an AUC of 0.851, accuracy of 0.903, sensitivity of 0.714, and specificity of 0.958 were achieved. While pre-treatment USG was significantly different (P = 0.002) between both groups, it did not show enhanced prediction over ADMA, nor in multivariate modeling.

CONCLUSIONS AND CLINICAL IMPORTANCE

Urinary ADMA can accurately predict post-131I azotemia in hyperthyroid cats becoming euthyroid after 131I treatment. These findings can aid clinicians in managing owner expectations and modify treatment plans.

Evaluation of serum insulin-like growth factor 1 concentrations in non-diabetic cats with chronic kidney disease

Feline hypersomatotropism (HST) can develop in both diabetic and non-diabetic cats, but studies evaluating the prevalence of HST in cats without diabetes mellitus (DM) are lacking. The aims of the study were to evaluate circulating insulin-like growth factor 1 (IGF-1) in non-diabetic cats with chronic kidney disease (CKD), to assess whether there is a correlation between general test of renal function and IGF-1 concentration in cats with CKD, and to screen this population for the presence of HST. In this prospective study, one hundred fifty-four non-diabetic cats (n = 154) with CKD from referral centers in Buenos Aires (Argentina) were evaluated. Serum IGF-1 concentration was measured as part of the routine tests for CKD and compared with a healthy control group of 50 cats without CKD. The median serum IGF-1 concentration in the total population of cats with CKD was 500 ng/mL (range 34-1593 ng/mL). Median serum IGF-1 concentrations of cats with IRIS stage 1 (n = 13), stage 2 (n = 86), stage 3 (n = 40) and stage 4 (n = 15) of CKD were 230 ng/mL (range 58-951 ng/mL), 473 ng/mL (range 34-1456 ng/mL), 597 ng/mL (range 123-1593 ng/mL), 569 ng/mL (range 123-1045 ng/mL), respectively. None of the cats in the control group had IGF-1 concentration >1000 ng/mL (median 505 ng/mL, range 114-720 ng/mL). There was a positive linear correlation between serum IGF-1 and creatinine concentrations in cats with CKD (r= 0.22, 95% confidence interval 0.06-0.37 P=0.005). A proportion of 5.8% (95% confidence interval 2.7-10.8%) of non-diabetic cats with CKD had markedly increased IGF-1 concentrations (cut-off IGF-1 >1000 ng/mL). Pituitary enlargement was detected on computed tomography in 3/4 of these cases. Eighteen cats (11.6%) had serum IGF-1 concentrations in the "grey zone" between 800 and 1000 ng/mL. A small proportion of non-diabetic cats with CKD had an IGF-1 concentration in a range that is consistent with HST in diabetic cats. Likewise, the progression of CKD in cats without DM correlates with increases in serum IGF-1 concentrations.

Renal Biomarkers in Companion Animals-A Review

Recent advancements in molecular biology have led to the discovery of potential biomarkers for the diagnosis of acute kidney disease (AKD) and chronic kidney disease (CKD). The use of multiple biomarkers in the diagnosis of kidney disease has the potential to enhance both specificity and sensitivity, enabling early detection and intervention that could ultimately reduce morbidity and mortality rates. This review provides an overview of studies on urine and blood biomarkers and examines their utility and significance in various clinical settings. Further and continuous research is needed to support the application of these biomarkers in clinical practice to facilitate early diagnosis, guidance for different interventions, and the monitoring of disease progression.

Association of Serum Symmetric Dimethylarginine Concentrations and Inflammation in Cats

BACKGROUND

Serum symmetric dimethylarginine (SDMA) concentrations are higher in some hyperthyroid cats with normal renal function, presumably due to increased protein catabolism.

OBJECTIVES

To investigate if SDMA is higher in cats with inflammation (defined as elevated serum amyloid A [SAA]).

ANIMALS

Twenty-eight cats: 12 with elevated SAA concentrations (> 3.9 μg/mL) and 16 with normal SAA.

METHODS

Retrospective case control study. Cats presenting to a referral institution between 2016 and 2022 with a documented SAA were identified. Individuals with renal and extrarenal factors known to affect SDMA were excluded. SDMA was measured from stored serum samples. Comparisons were made using the Mann-Whitney U test, and correlations assessed using Spearman's correlation coefficient. Data are presented as median [minimum-maximum].

RESULTS

SDMA was not significantly different between cats with elevated SAA and normal SAA (11 [5-17] μg/dL vs. 13 [9-21] μg/dL, respectively; p = 0.28). There was no correlation between SDMA and SAA (rs = -0.105; p = 0.594) or serum TT4 concentrations (rs = -0.023; p = 0.906). No difference in age or USG was present between elevated SAA and normal SAA groups (p = 0.908 and p = 0.165, respectively). Serum urea and creatinine concentrations were both significantly lower in cats with elevated SAA compared to those with normal SAA (6.3 [3.6-8.8] mmol/L vs. 8.4 [6.2-10.5] mmol/L; p = 0.008, and 96 [62-129] μmol/L vs. 118 [90-147] μmol/L; p = 0.008, respectively).

CONCLUSIONS AND CLINICAL IMPORTANCE

SDMA might be a more representative biomarker of GFR during inflammatory states, provided other confounding factors that affect SDMA are eliminated.

Kidney function, but not nitrogen excretion differs between Brown Swiss and Holstein dairy cows

Brown Swiss (BS) cows have greater urea concentrations in milk and blood compared with Holstein (HO) cows. We tested the hypothesis that BS and HO cows differ in kidney function and nitrogen excretion. Blood, saliva, urine, and feces were sampled in 31 multiparous BS and 46 HO cows kept under identical feeding and management conditions. Samples were collected at different lactational stages after the monthly DHIA control test-day. To test the glomerular filtration rate (GFR) and urea excretion, concentrations of creatinine and urea were measured in serum, urine, and saliva. As an additional marker to estimate GFR, we determined symmetric dimethylarginine (SDMA) in serum. Feces were analyzed for dry matter content and nitrogen concentration. Data on milk urea and protein concentrations, and daily milk yield were obtained from the monthly DHIA test-day records. The effects of breed, time, and parity number on blood, saliva, urine, feces, and milk parameters were evaluated with the GLM procedure with breed, time, and parity number as fixed effects. Differences between BS and HO were assessed by the Tukey-corrected t-test at P < 0.05. Concentrations of urea, creatinine, and SDMA in serum, were greater in BS than in HO cows (P < 0.01): 5.46 ± 0.19 vs 4.72 ± 0.13 mmol/L (urea), 105.96 ± 2.23 vs 93.07 ± 1.50 mmol/l (creatinine), and 16.78 ± 0.69 vs 13.39 ± 0.44 µg/dL (SDMA). We observed a greater urea concentration in BS cows (25.8 ± 0.7 vs 21.8 ± 0.7 mg/dL) and protein content in milk (3.70 ± 0.08 vs 3.45 ± 0.07%) than in HO cows (P < 0.01). Urea and creatinine concentrations in urine and saliva did not differ among breeds. No differences between BS and HO were observed for milk yield, fecal DM, and fecal nitrogen content. Dry matter intake and body weight were similar in BS and HO cows (P > 0.05). Despite greater urea, creatinine, and SDMA concentrations in blood as well as a higher milk urea content in BS compared with HO, respective concentrations in urine did not differ between breeds. In conclusion, our results demonstrate a lower renal GFR in BS compared with HO cows, thereby contributing to the greater plasma urea concentration in BS cows. However, estimation of nitrogen excretion via milk, urine, and feces does not entirely reflect nitrogen turnover within the animal.

International Renal Interest Society best practice consensus guidelines for the diagnosis and management of acute kidney injury in cats and dogs

Acute kidney injury (AKI) is defined as an injury to the renal parenchyma, with or without a decrease in kidney function, as reflected by accumulation of uremic toxins or altered urine production (i.e., increased or decreased). AKI might result from any of several factors, including ischemia, inflammation, nephrotoxins, and infectious diseases. AKI can be community- or hospital-acquired. The latter was not previously considered a common cause for AKI in animals; however, recent evidence suggests that the prevalence of hospital-acquired AKI is increasing in veterinary medicine. This is likely due to a combination of increased recognition and awareness of AKI, as well as increased treatment intensity (e.g., ventilation and prolonged hospitalization) in some veterinary patients and increased management of geriatric veterinary patients with multiple comorbidities. Advancements in the management of AKI, including the increased availability of renal replacement therapies, have been made; however, the overall mortality of animals with AKI remains high. Despite the high prevalence of AKI and the high mortality rate, the body of evidence regarding the diagnosis and the management of AKI in veterinary medicine is very limited. Consequently, the International Renal Interest Society (IRIS) constructed a working group to provide guidelines for animals with AKI. Recommendations are based on the available literature and the clinical experience of the members of the working group and reflect consensus of opinion. Fifty statements were generated and were voted on in all aspects of AKI and explanatory text can be found either before or after each statement.

Symmetric dimethylarginine correlates with the urea, creatinine, potassium, and clinical scores in feline urethral obstructions

BACKGROUND

A urethral obstruction (UO) is an emergency commonly observed in male cats, which can result in significant clinical and laboratory alterations, leading to complications and death.

OBJECTIVES

This study aimed to correlate symmetric dimethylarginine (SDMA) with the urea, creatinine, potassium, and bicarbonate levels in cats with UO. In addition, the correlation between clinical score and time of obstruction was evaluated.

METHODS

Thirty male cats were selected and allocated into a control group (CG, n = 13) and an obstruction group (OG, n = 17). The laboratory analyses were conducted before treatment (M0) and at different times after treatment (12 h [M12], 24 h [M24], and 48 h [M48]). Correlations were established between SDMA and creatinine, urea, bicarbonate, potassium, time of obstruction, and the clinical score.

RESULTS

A strong correlation (r > 0.6) was observed between SDMA and creatinine, urea, and potassium in the OG. Furthermore, there was substantial agreement (kappa value) between SDMA and creatinine at M24. A higher clinical score was associated with a longer time of obstruction. In the OG, at M48, the SDMA and creatinine levels were 50% and 41.2% higher, respectively.

CONCLUSIONS

A correlation was observed between SDMA and creatinine in obstructed cats, and significant agreement between these values was observed 24 h after the unblocking treatment. A correlation among SDMA, urea, and potassium was observed. Approximately 9% more cats continued to have elevated SDMA levels after 48 h of treatment compared to creatinine. This suggests a slightly lower sensitivity of the latter biomarker but does not exclude the possibility of congruent and normalized values after a longer evaluation period.

Effect of storage temperature and time on measurement of serum symmetric dimethylarginine concentration using point-of-care and commercial laboratory analyzers in cats and dogs

BACKGROUND

Stability of serum symmetric dimethylarginine (sSDMA) during short- and long-term storage has not been assessed for the immunoassay of the Point-of-Care IDEXX Catalyst DX (POC) analyzer and the Enzyme Multiplied Immunoassay Technique of IDEXX commercial laboratory (CL). Also, the agreement between both analyzers is questioned.

OBJECTIVES

To determine (a) the effect of storage time and temperature on sSDMA measured by POC and CL; (b) the agreement between sSDMA measured by POC and CL; and (c) the imprecision of the POC.

ANIMALS

Serum of cats (n = 17) and dogs (n = 18) with a range of SDMA concentrations (6 to >100 μg/dL).

METHODS

Based on an equivalence trial with predefined equivalence range (-3.0 to +3.0 μg/dL) and using T0 as baseline, stability was evaluated after 24 hours at 22°C and 4°C (POC); after 7 days at 4°C (POC and CL) and after 10 and 24 months at -24°C and -80°C (CL). Bland-Altman plots enabled method comparison. Imprecision of the POC was assessed by duplicate sSDMA measurements at T0.

RESULTS

The POC analyzer produced equivalent sSDMA measurements if samples were stored for 24 hours at 4°C (95% confidence interval [CI]: -2.5-2.0 μg/dL), but not when stored for 24 hours at room temperature (RT; 95% CI: -4.1 to 0.5 μg/dL) or after 7 days at 4°C (95% CI: -3.6-1.0 μg/dL). The CL analyzer was less affected by preanalytical variation with clinically similar results obtained when samples were stored for 7 days at 4°C (95% CI: -2.2 to 2.4 μg/dL) and for at least 24 months at -24°C (95% CI: -1.7 to 2.9 μg/dL) and -80°C (95% CI: -1.5 to 3 μg/dL). A relevant mean difference of -2.3 μg/dL between both analyzers was found. Duplicate POC measurements were equivalent (95% CI: -2.6 to 2.0 μg/dL).

CONCLUSIONS

Delayed analysis may significantly change sSDMA depending on storage and measurement conditions. Interchangeable use of assays should be done with caution because analytical variation could be interpreted as clinically relevant change.